COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202CRS" target="_blank" >RIV/61988987:17110/21:A2202CRS - isvavai.cz</a>

Alternative codes found

RIV/00843989:_____/21:E0109241

Result on the web

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000726733000016" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000726733000016</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S2352-3026(21)00278-7" target="_blank" >10.1016/S2352-3026(21)00278-7</a>

Result language

angličtina

Original language name

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

Original language description

Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for infections and infection-related mortality. The risk for infection with SARS-CoV-2 virus and resulting mortality is also increased, emphasising the importance of protecting patients by vaccination. Available data in patients with multiple myeloma suggest a suboptimal anti-SARS-CoV-2 immune response, meaning a proportion of patients are unprotected. Factors associated with poor response are uncontrolled disease, immunosuppression, concomitant therapy, more lines of therapy, and CD38 antibody-directed and B-cell maturation antigen-directed therapy. These facts suggest that monitoring the immune response to vaccination in patients with multiple myeloma might provide guidance for clinical management, such as administration of additional doses of the same or another vaccine, or even temporary treatment discontinuation, if possible. In those who do not exhibit a good response, prophylactic treatment with neutralising monoclonal antibody cocktails might be considered. In patients deficient of a SARS-CoV-2 immune response, adherence to measures for infection risk reduction is particularly recommended. This consensus was generated by members of the European Multiple Myeloma Network and some external experts. The panel members convened in virtual meetings and conducted an extensive literature research and evaluated recently published data and work presented at meetings, as well as findings from their own studies. The outcome of the discussions on establishing consensus recommendations for COVID-19 vaccination in patients with multiple myeloma was condensed into this Review.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lancet Haematology

ISSN

2352-3026

e-ISSN

—

Volume of the periodical

8

Issue of the periodical within the volume

12

Country of publishing house

GB - UNITED KINGDOM

Number of pages

13

Pages from-to

'E934'-'E946'

UT code for WoS article

000726733000016

EID of the result in the Scopus database

—